08 September 2008
Ann Transplant 2008; 13(3): 27-29 :: ID: 868535
Background: We have found no study conducted economic issues on patient outcomes after heart transplantation (HTx) in China for further development.
Material/Methods: From May 2004 to February 2006, there were 10 transplants performed in 9 male patients in our center: 1 heart lung recipient and 8 heart recipient. Among them, 7 lacked health insurance and 2 had insurance.
Results: Their ages were between 24 years and 43 years (mean 39 years). The number of hospitalizations, number of days in hospital per admission, number of emergency room visits and mean left ventricular ejection fraction (LVEF) in the year before operation were 5.5, 54, 8.1 and 0.19 respectively. After operation, these figures decreased significantly to 1.7 (P<0.05), 18 (P<0.05), 1.1 (P<0.05) and 0.70 (P<0.05) respectively. During the follow up of 370~930d, one of the 9 patients who lacked health insurance died of acute rejection due to stopping mycophenolate mofetil (MMF) 7 months after operation and the heart lung recipient who also lacked health insurance died of pulmonary infection 1 year later. All patients who lacked health insurance experience emotional distress.
Conclusions: HTx is a good treatment for selected patients with end-stage heart failure (ESHF) and future research is to be expected in the fields of insurance coverage to improve the quality of life and the Chinese transplant group should be commended for their courageous work in the treatment of end stage heart disease under challenging circumstances.
Keywords: Heart Transplantation, end-stage heart failure, Quality of Life
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588